Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Vnitrni Lekarstvi|February 5, 2020
Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk&#8221Richard Češka
Vnitrni Lekarstvi|December 15, 2015
[PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®]Richard Češka
Casopis Lekaru Ceskych|December 8, 2017
[Hyperlipoprotienemias and (not only) atherosclerosis: fragments from history and present]Richard Češka
Vnitrni Lekarstvi|February 19, 2015
[Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond]Richard Češka
Vnitrni Lekarstvi|February 2, 2019
Comments on the most important and recent studies involving PCSK9iRichard Češka
Vnitrni Lekarstvi|September 15, 2016
[Estimating the prevalence of potential drug interactions in patients treated with 5 and more drugs in the Czech Republic and Slovac Repuplic]Richard Češka, Ivan Tkáč
Casopis Lekaru Ceskych|August 15, 2025
Dyslipidemias as rare diseasesŠárka Tesařová, Richard Češka
Vnitrni Lekarstvi|January 21, 2015
[News in lipid lowering treatment]Michal Vrablík, Richard Češka
Vnitrni Lekarstvi|February 5, 2020
Vascular ageOndřej Petrák, Richard Češka
Vnitrni Lekarstvi|February 2, 2019
Consensus statement of professional associations on prescribing of PCSK9-inhibitorsRichard Češka, Miloš Táborský, Michal Vrablík
Pageof 4